Skip to content
2000
Volume 14, Issue 1
  • ISSN: 1574-8855
  • E-ISSN: 2212-3903

Abstract

Background: Cytotherapy products can be described as “living drugs”. Cytotherapy is the swiftest growing fields in the treatment of cancer, heart diseases, aging population and neuromuscular ailments. Biomimetic approaches are processes developed by humans such as devices, substances, or systems that mimic nature or natural processes. Objective and Method: It aims at developing a base for personalized medicine with allogeneic, autologous and xenogenic therapies where cells are modified for target selection. Such drug delivery methods appear to be complex and challenging. Literature for approximately past two decades was collected and reviewed for the present article. Results and Conclusion: The opportunities and challenges in cytotherapy have been classified, discussed and demystified. Various process inputs, materials and process conditions required in bioprocessing and preservation have been discussed at length. The review also focuses on the regulatory requirements in India, Europe and U.S.

Loading

Article metrics loading...

/content/journals/cdth/10.2174/1574885514666181220092721
2019-04-01
2025-10-02
Loading full text...

Full text loading...

/content/journals/cdth/10.2174/1574885514666181220092721
Loading

  • Article Type:
    Review Article
Keyword(s): allogeneic; biomimetic; bioprocessing; Cytotherapy; nanomedicine; regulatory requirements
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test